Naivek, a peptide fusion bio-specialized company, announced on the 6th that it has been selected as a biotech showcase presenter at the ‘JP Morgan Healthcare Conference 2025 (hereinafter JPM 2025).’
At this showcase, Naivek plans to introduce its core pipelines, including ‘NP-201,’ the world’s first regenerative mechanism inflammatory bowel disease treatment, and the research achievements of its peptide-based drug delivery platform technology ‘PEPTARDEL,’ accelerating collaboration with global pharmaceutical companies.
The JPM Healthcare Conference is the world’s largest pharmaceutical and biotech event held annually in January. Approximately 10,000 industry experts and investors gather to share research results and technologies and discuss business cooperation in a networking venue. The biotech showcase is a program linked to JPM 2025 that supports biotech companies and investors in seeking collaboration during the event period.
Naivek’s NP-201 is a novel drug that dramatically inhibits fibrosis, the cause of inflammation. While existing treatments focus on blocking the fibrosis process, NP-201 is characterized by enabling fundamental tissue function recovery based on regenerative mechanism peptides. After receiving approval for clinical phase 1b/2a of NP-201 in Australia last November, Naivek has commenced global clinical trials. It also plans to separately pursue a phase 2 clinical trial with the U.S. Food and Drug Administration (FDA) for NP-201 in the first half of this year.
Naivek is also developing NP-201 as an obesity treatment. NP-201 enables weight loss without muscle loss through a mechanism that directly inhibits adipocyte proliferation and fat accumulation. Utilizing proprietary peptide-based technology, it maximizes drug delivery efficiency while minimizing side effects. The company explains that NP-201 is evaluated as a new drug candidate with the potential to overcome the limitations of the existing obesity treatment market, which mainly focuses on appetite suppression.
Naivek’s proprietary drug delivery platform technology, PEPTARDEL, enables precise and effective drug delivery while minimizing side effects by utilizing peptides. Currently, Naivek is actively developing sustained-release formulations and oral formulations based on PEPTARDEL. At JPM 2025, the company is preparing follow-up meetings with global companies that have shown interest in PEPTARDEL technology at previous events such as ‘Bio USA’ and ‘Bio Europe.’
A Naivek representative stated, “Through meetings with global top-tier companies in the metabolic disease field, we plan to conduct detailed discussions to expedite the commercialization of NP-201, which is currently undergoing clinical trials in Australia,” adding, “Through this, we will present a new paradigm in the obesity and metabolic disease treatment market.”
He continued, “In addition to developing various pipelines applying PEPTARDEL, we will expand the application of our proprietary drug delivery platform technology through joint research and collaboration with global pharmaceutical companies,” adding, “We expect that cooperation with global pharmaceutical companies will further expand starting from JPM 2025 this year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
